Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history

Ann Allergy Asthma Immunol. 2019 Aug;123(2):222-224.e1. doi: 10.1016/j.anai.2019.04.028. Epub 2019 May 8.

Authors

Affiliations

¹ David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: jcorren@ucla.edu.
² Washington University School of Medicine, St Louis, Missouri.
³ Asthma and Allergy Center, Bellevue, Nebraska.
⁴ University of Cincinnati, Cincinnati, Ohio; Bernstein Clinical Research Center, Cincinnati, Ohio.
⁵ Sanofi, Bridgewater, New Jersey.
⁶ Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
⁷ Sanofi, Chilly-Mazarin, France.

PMID: 31075309
DOI: 10.1016/j.anai.2019.04.028

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / drug therapy*
Disease Outbreaks / prevention & control
Humans
Interleukin-13 / antagonists & inhibitors
Interleukin-4 / antagonists & inhibitors
Lung / physiology

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
IL4 protein, human
Interleukin-13
Interleukin-4
dupilumab

Associated data

ClinicalTrials.gov/NCT01854047